Patients with elevated gastrointestinal lesions undergoing endoscopic ultrasonography
Conditions
Interventions
Test group (DEX+Es group),:Dextrmedetomidine nasal spray and Esketamine nasal drops
Control group (MID+SUF group):Intravenous combination of midazolam and sufentanil
Sponsors
Chui Yang Liu Hospital affiliated to Tsinghua University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged between 18 and 60 years; 2. American Society of Anesthesiologists classification (ASA): I-III; 3. BMI index of 19-28 kg/m^2; 4. Patients planning to undergo endoscopic ultrasonography; 5. Compliant with ethics, patients voluntarily participate in the trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Nasal diseases (rhinitis, nasal polyps, nosebleeds, history of nasal surgery); 2. Patients who require tracheal intubation and general anesthesia for examination; 3. Patients with blood pressure >= 180/110 mmHg (WHO-ISH hypertension guideline grade 3 hypertension) or blood pressure <= 90/60 mmHg; 4. Individuals who have experienced arrhythmia, unstable angina, or myocardial infarction within the past 3 months; 5. Bradycardia (heart rate<50 beats/minute) or severe heart block (2nd or 3rd degree atrioventricular block); 6. Patients with underlying respiratory diseases (severe asthma, severe obstructive pulmonary disease, or severe bronchitis); 7. Respiratory rate<10 times/minute; 8. Snoring patients or those with Mallampati grade = 3 who have difficult airways; 9. Individuals with severe liver and kidney complications; 10. Patients with digestive tract abnormalities affecting the timing of endoscopy or those who have undergone digestive surgery before; 11. Pregnant and lactating women; 12. Individuals who are allergic to anesthetic drugs (benzodiazepines, opioids, dexmedetomidine and esketamine) and any of their components; 13. Patients who refuse to sign the informed consent form, or can not be follow up; 14. Patients deemed unsuitable by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MOAA/S score;The occurrence of respiratory depression;Tolerance to endoscopic ultrasonography; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemodynamic indicators: changes in heart rate, blood pressure, respiratory rate, and SpO2 in patients after administration;Adverse reactions: such as nasal mucosal irritation symptoms, bradycardia, hypotension, hypertension, nausea and vomiting, xerostomia, dizziness, etc.;Satisfaction evaluation; | — |
Countries
China
Contacts
Public ContactYang Wangyan
Chui Yang Liu Hospital affiliated to Tsinghua University
Outcome results
None listed